Kiora Pharmaceuticals price target raised to $3.50 from $2 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen raised the firm’s price target on Kiora Pharmaceuticals to $3.50 from $2 and keeps a Buy rating on the shares. The analyst says KIO-301 showed meaningful vision improvement in the ABACUS trial.